Last reviewed · How we verify
NCT02658708
Bright Light on Fatigue in Women Being Treated for Breast Cancer
Phase 1 trial testing Bright blue-green light using light visor cap in Breast Neoplasms in 19 participants. Completed in 9 May 2017.
9 May 2017
Quick facts
| Lead sponsor | Washington University School of Medicine |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 12 October 2015 |
| Primary completion | 9 May 2017 |
| Estimated completion | 9 May 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bright blue-green light using light visor cap
- Dim red light using light visor cap
- European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire
- Epworth Sleepiness Scale
- Pittsburgh Sleep Quality Index
- Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance
- Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue
- Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)
- Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)
- Horne-Ostberg Morningness-Eveningness Questionnaire
- Daily Fatigue and Sleep Log
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
- Breast Cancer — all drugs for Breast Cancer →
- Cancer of Breast — all drugs for Cancer of Breast →
- Cancer of the Breast — all drugs for Cancer of the Breast →
Sponsor
Washington University School of Medicine
Who can join
21 and older, female only, with Breast Neoplasms or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This proposed study will examine feasibility and implement therapeutic bright light that is tailored to the individual's circadian typology to estimate its therapeutic effects on sleep/wake patterns and fatigue in breast cancer patients undergoing chemotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chronotherapy: Intuitive, Sound, Founded…But Not Broadly Applied.
Selfridge JM, Gotoh T, Schiffhauer S, Liu J, et al · · 2016 · cited 51× · PMID 27699644 · DOI 10.1007/s40265-016-0646-4 -
Bright light shows promise in improving sleep, depression, and quality of life in women with breast cancer during chemotherapy: findings of a pilot study.
Wu HS, Davis JE, Chen L. · · 2021 · cited 16× · PMID 33478260 · DOI 10.1080/07420528.2021.1871914
Verify or expand the search:
- PubMed search for NCT02658708
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Washington University School of Medicine trials
Trials by the same sponsor.
- NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
- NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
- NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
- NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02658708 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
- Last refreshed: 25 September 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02658708.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing